CME Presentations

FOP

Presentations

Speakers

  • Ellen Elias, MD, FAAP, FACMG

    Ellen Elias, MD, FAAP, FACMG

    Ellen Elias, MD, FAAP, FACMG

    Professor of Pediatrics and Genetics

    Ellen Elias, MD, FAAP, FACMG, is Professor of Pediatrics and Genetics at the University of Colorado School of Medicine. She directs the Special Care Clinic, where around 5,000 children with medical complexity receive primary care and consultative care for their genetic/medical /developmental disorders. Dr. Elias was one of the original geneticists to discover the cause of Smith-Lemli-Opitz syndrome (SLOS) and continue to pursue clinical research regarding the care and management of patients with this disorder. She is currently investigating the use of antioxidants to slow down progression of retinal disease in patients with SLOS. Furthermore, Dr. Elias was a co-investigator in a CDC sponsored multiple institutional study called CADDRE, studying dysmorphic features in children with Autism.

    Session Appearances

    Fibrodysplasia Ossificans Progressiva: Early Recognition and Emerging Disease-modifying Treatments to Improve Outcomes

  • Richard Keen, MD

    Richard Keen, MD

    Richard Keen, MD

    Director of the Metabolic Bone Disease Unit

    Richard Keen, MD, is the Director of the Metabolic Bone Disease Unit at the Royal National Orthopaedic Hospital, London, UK. Also, he heads a team involved in the clinical care of patients with a wide range of bone diseases. Dr Keen is experienced in the management of patients with osteoporosis and other rarer bone diseases including osteogenesis imperfecta, X-linked hypophosphataemic rickets, fibrous dysplasia and fibrodysplasia ossificans progressiva (FOP). He works with athletes and has expertise in management of bone-related problems such as stress fractures and myositis ossificans. Furthermore, he is a member of the International Clinical Council on FOP, a member of the Medical Advisory Board to the FOP Registry, and chair of the UK Brittle Bone Society’s Scientific Advisory Board.

    Session Appearances

    Fibrodysplasia Ossificans Progressiva: Early Recognition and Emerging Disease-modifying Treatments to Improve Outcomes

CME Information

Global LogoPQH Logo

Fibrodysplasia Ossificans Progressiva: Early Recognition and Emerging Disease‐modifying Treatments to Improve Outcomes

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC in collaboration with the National Organization for Rare Disorders, Inc. (NORD) and International Fibrodysplasia Ossificans Progressiva Association (IFOPA).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.

TUITION

Complimentary

JOINT ACCREDITATION STATEMENT

JointlyAccreditedProvider Logo In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Enduring Material
The enduring material will be available from January 27, 2023 to January 27, 2024.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Recognize the signs and symptoms of FOP and the impact of the disease on patient and family QoL
  • Confirm FOP diagnosis by performing or referring for genetic testing
  • Apply current clinical evidence and management guidelines to reduce and manage the occurrence of flare-ups and prevent or minimize ongoing ossification
  • Describe the efficacy, safety, and place in treatment of emerging therapies for patients with FOP

TARGET AUDIENCE

The target audience for the activity are orthopedists, rare-bone specialists, rheumatologists, pediatric rheumatologists, and pediatricians.

ESTIMATED TIME TO COMPLETE

1 hour

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.ClinicalSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Name of Faculty or Presenter Reported Financial Relationship
Ellen Roy Elias, MD, FAAP, FACMG
Professor, Pediatrics and Genetics
Doctor, Special Care Clinic
Children’s Hospital Colorado
University of Colorado School of Medicine
Nothing to disclose
Richard Keen, MD, PhD, FRCP
Professor in Metabolic Bone Disease
Royal National Orthopaedic Hospital NHS Trust
Stanmore, UK
 Grant/Research Support: Incyte, Ipsen, Regeneron
Speakers Bureau/Honoraria for non-CME: Ipsen
Consultant/Advisory Board: Ipsen, Regeneron

The PIM planners and managers have nothing to disclose. The PlatformQ Health Education, LLC planners and others have nothing to disclose.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.